Speciality
Spotlight

 




 


Neurology


 

 




Ischemic
Strokes

  

  • Jailard
    A, for the Multicenter Stroke Trial – Europe Group
    [Univ. Hosp. Grenoble, France]

    Hemorrhagic
    Transformation in Acute Ischemic Stroke : The Mast-E
    Study


    Stroke
    30 : 1326-1332, 1999

        

    The
    risk factors for hemorrhagic transformation [HT],
    following the administration
    of streptokinase after stroke, have not been
    well studied. The occurrence and the late predictors
    of cerebral HT in both strptokinase and placebo group
    was investigated in a post hoc analysis of data from
    the double-blind, controlled, Multicenter Acute Stroke
    Trial Europe [MAST-E] Study.

        

    Three hundred and ten patients received either
    1,500,000 units of streptokinase [n=156] or placebo
    [n=154], administered intravenously, within 6 hours of
    the onset of stroke symptoms. Mortality and severe
    disability were assessed at 6 months’ followup,
    safety was evaluated at 10 days, and asymptomatic HT
    and symptomatic HT [SHT] were evaluated by CT within 5
    days.

         

    HT was seen in 96 patients [61%] in the streptokinase
    group [37 with SHT] and
    in 61 patients [31%] in the placebo group [ 4 with SHT].
    Patients with SHT were significantly more
    likely to have diabetes, atrial fibrillation, no
    heparin use, streptokinase treatment, and early CT
    signs.

         

    According
    to the study, early CT signs, were strong predictors
    of HT and SHT in stroke patients, particularly in the
    streptokinase treated cases.
    Patients with decreased level of consciousness
    were more likely to get SHT.

         

 



 

 

Speciality Spotlight

 

 
Neurology
 

 

Ischemic Strokes
  

  • Jailard A, for the Multicenter Stroke Trial – Europe Group [Univ. Hosp. Grenoble, France]
    Hemorrhagic Transformation in Acute Ischemic Stroke : The Mast-E Study
    Stroke 30 : 1326-1332, 1999
        
    The risk factors for hemorrhagic transformation [HT], following the administration of streptokinase after stroke, have not been well studied. The occurrence and the late predictors of cerebral HT in both strptokinase and placebo group was investigated in a post hoc analysis of data from the double-blind, controlled, Multicenter Acute Stroke Trial Europe [MAST-E] Study.
        
    Three hundred and ten patients received either 1,500,000 units of streptokinase [n=156] or placebo [n=154], administered intravenously, within 6 hours of the onset of stroke symptoms. Mortality and severe disability were assessed at 6 months’ followup, safety was evaluated at 10 days, and asymptomatic HT and symptomatic HT [SHT] were evaluated by CT within 5 days.
         
    HT was seen in 96 patients [61%] in the streptokinase group [37 with SHT] and in 61 patients [31%] in the placebo group [ 4 with SHT]. Patients with SHT were significantly more likely to have diabetes, atrial fibrillation, no heparin use, streptokinase treatment, and early CT signs.
         
    According to the study, early CT signs, were strong predictors of HT and SHT in stroke patients, particularly in the streptokinase treated cases. Patients with decreased level of consciousness were more likely to get SHT.
         

 

 

By |2022-07-20T16:42:27+00:00July 20, 2022|Uncategorized|Comments Off on Ischemic Strokes

About the Author: